The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence
Open accessAbstract
The endocannabinoid signaling system is a widespread, neuromodulatory system in brain and is also widely utilized in the periphery to modulate metabolic functions and the immune system. Preclinical data demonstrate that endocannabinoid signaling is an important stress buffer and modulates emotional and cognitive functions. These data suggest the hypothesis that endocannabinoid signaling could be dysfunctional in a number of mental disorders. Genetic polymorphisms in the human genes for two important proteins of the endocannabinoid signaling system, the CB1 cannabinoid receptor (CB1R) and fatty acid amide hydrolase (FAAH), have been explored in the context of normal and pathological conditions. In the case the gene for FAAH, the mechanistic relationships among the common genetic polymorphism, the expression of the FAAH protein and its likely impact on endocannabinoid signaling are understood. However, multiple polymorphisms in the gene for the CB1R occur and are associated with human phenotypic differences without an understanding of the functional relationships among the gene, mRNA, protein and protein function. The endocannabinoid ligands are found in the circulation and several studies have identified changes in their concentrations under various conditions. These data are reviewed for the purpose of generating hypotheses and to encourage further studies in this very interesting and important area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“In addition, a meta-analysis of cytokines in major depression demonstrated an increase in circulating TNFalpha and IL-6 in depressed patients (Dowlati et al., 2010).”
BackgroundDetermination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“A series of biochemical studies characterized the target of THC as a G proteincoupled receptor (Howlett and Fleming, 1984, Howlett, 1985, Howlett, 1987, Devane et al., 1988).”
BackgroundCortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
Steptoe, A., Hamer, M., & Chida, Y. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.03.011 · Cited by 1,278
Psychobiology and molecular genetics of resilience
Feder, A., Nestler, E. J., & Charney, D. S. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2649 · Cited by 1,272 · cited 1×
“However, most people are resilient to the effects of stress and the biological processes that underlie stress resilience are beginning to be understood (Feder et al., 2009).”
BackgroundEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 2×
“A significant occurrence of depressed mood was found in patients given the CB1R antagonist, rimonabant, for weight loss and obesity-related metabolic disorders (Christensen et al., 2007, de Mattos Viana et al., 2009).”
BackgroundMethodGlass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Cannabis use and mental health in young people: cohort study.
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., & Hall, W. (2002) · BMJ · doi:10.1136/bmj.325.7374.1195 · Cited by 997
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871
Genetic and environmental influences on human psychological differences
Bouchard, T. J., & McGue, M. (2003) · Journal of Neurobiology · doi:10.1002/neu.10160 · Cited by 870
Kendler, K. S., Kuhn, J., & Prescott, C. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.631 · Cited by 799
Distribution of cannabinoid receptors in the central and peripheral nervous system
Mackie, K. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_10 · Cited by 744 · cited 3×
“CB1R are also expressed by peripheral neurons (Mackie, 2005).”
BackgroundInfluentialExploring the association between cannabis use and depression.
Degenhardt, L., Hall, W., & Lynskey, M. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00437.x · Cited by 587 · cited 1×
“Heavy cannabis use and major depression are comorbid in clinical and community populations (Degenhardt et al., 2003, Lynskey et al., 2004) and several prospective studies have found that cannabis use precedes the diagnosis of depression (Bovasso, 2001, Patton et al., 2002, Rey and Tennant, 2002).”
BackgroundC/EBP is an immediate-early gene required for the consolidation of long-term facilitation in Aplysia
Alberini, C. M., Ghirardl, M., Metz, R., & Kandel, E. R. (1994) · Cell · doi:10.1016/0092-8674(94)90386-7 · Cited by 523
Endocannabinoid signaling system and brain reward: emphasis on dopamine
GARDNER, E. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.032 · Cited by 387
Comorbidity of Fibromyalgia and Psychiatric Disorders
Arnold, L. M., Hudson, J. I., Keck, P. E., Auchenbach, M. B., Javaras, K. N., & Hess, E. V. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0807 · Cited by 382
Hill, M. N., Patel, S., Carrier, E. J., Rademacher, D. J., Ormerod, B. K., Hillard, C. J., & Gorzalka, B. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300601 · Cited by 363
Self-citationHippocampus and Amygdala Morphology in Attention-Deficit/Hyperactivity Disorder
Plessen, K. J., Bansal, R., Zhu, H., Whiteman, R., Amat, J., Quackenbush, G. A., Martin, L., Durkin, K., Blair, C., Royal, J., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.795 · Cited by 347 · cited 2×
“ADHD, in addition to impulsivity, also involves emotional dysregulation and there is evidence to support increased amygdalar reactivity (Plessen et al., 2006); differences in prefrontal-limbic circuitry (Durston et al.”
BackgroundHill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.03.013 · Cited by 328
Richardson, D., Pearson, R. G., Kurian, N., Latif, M. L., Garle, M. J., Barrett, D. A., Kendall, D. A., Scammell, B. E., Reeve, A. J., & Chapman, V. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2401 · Cited by 303
Systemic inflammation in heart failure – The whys and wherefores
Yndestad, A., Kristian Damås, J., Øie, E., Ueland, T., Gullestad, L., & Aukrust, P. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9196-2 · Cited by 294
Fraser, G. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00071.x · Cited by 283 · cited 1×
“A small study of the therapeutic benefit of nabilone, an CB1R agonist that is given orally, a majority of patients treated (72% of 47 patients total) experienced a significant reduction in intensity or complete elimination of nightmares (Fraser, 2009).”
BackgroundCaillé, S., Alvarez-Jaimes, L., Polis, I., Stouffer, D. G., & Parsons, L. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4403-06.2007 · Cited by 280
Chiang, K. P. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh216 · Cited by 278
Hill, M. N., Carrier, E. J., McLaughlin, R. J., Morrish, A. C., Meier, S. E., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05567.x · Cited by 246 · cited 7×
“Serum 2-AG concentrations were significantly decreased in patients with major depression compared to demographically matched controls (Hill et al., 2008b, Hill et al., 2009c).”
BackgroundInfluentialSelf-citationAmygdala reactivity to emotional faces predicts improvement in major depression
Canli, T., Cooney, R. E., Goldin, P., Shah, M., Sivers, H., Thomason, M. E., Whitfield-Gabrieli, S., Gabrieli, J. D. E., & Gotlib, I. H. (2005) · NeuroReport · doi:10.1097/01.wnr.0000174407.09515.cc · Cited by 174 · cited 2×
“…at odds with the finding that an A allele at rs1049353 is associated with increased striatal reactivity to happy faces (Chakrabarti et al., 2006) since higher responsiveness to positive social cues has been found to be associated with a favorable outcome in major depression (Canli et al., 2005).”
BackgroundCannabinoid-Induced Immune Suppression and Modulation of Antigen-Presenting Cells
Klein, T. W., & Cabral, G. A. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-005-9007-x · Cited by 172
Imaging brain response to reward in addictive disorders
Hommer, D. W., Bjork, J. M., & Gilman, J. M. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05898.x · Cited by 163
Motion Sickness, Stress and the Endocannabinoid System
Choukèr, A., Kaufmann, I., Kreth, S., Hauer, D., Feuerecker, M., Thieme, D., Vogeser, M., Thiel, M., & Schelling, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010752 · Cited by 140
Tyndale, R. F., Payne, J. I., Gerber, A. L., & Sipe, J. C. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30491 · Cited by 117
Plasma endocannabinoid levels in multiple sclerosis
Jean-Gilles, L., Feng, S., Tench, C. R., Chapman, V., Kendall, D. A., Barrett, D. A., & Constantinescu, C. S. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.07.021 · Cited by 100
Circulating endocannabinoid concentrations during orthostatic stress
Schroeder, C., Batkai, S., Engeli, S., Tank, J., Diedrich, A., Luft, F. C., & Jordan, J. (2009) · Clinical Autonomic Research · doi:10.1007/s10286-009-0026-1 · Cited by 26
Cited by
Endocannabinoid Signaling and Synaptic Function
Castillo, P. E., Younts, T. J., Chávez, A. E., & Hashimotodani, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.020 · Cited by 1,120
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 660
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
Endocannabinoid signalling in reward and addiction
Parsons, L. H., & Hurd, Y. L. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4004 · Cited by 481
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?
Hillard, C. J. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.130 · Cited by 445
Self-citation
Metadata
- Authors
- Hillard, C. J., Weinlander, K. M., & Stuhr, K. L.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 204
- Pages
- 207-229
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W1992557727
- Cited by
- 187
- References
- 36
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.